CLINICAL TRIALS PROFILE FOR SORIATANE

All Clinical Trials for SORIATANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00156247 ↗	Acitretin and Etanercept in Psoriasis	Completed	Connetics Corp.	Phase 2	2005-09-01	To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
NCT00156247 ↗	Acitretin and Etanercept in Psoriasis	Completed	University of Medicine and Dentistry of New Jersey	Phase 2	2005-09-01	To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
NCT01545284 ↗	Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis	Completed	Tribute Pharmaceuticals	Phase 2/Phase 3	2012-03-01	This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis .
NCT01545284 ↗	Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis	Completed	Innovaderm Research Inc.	Phase 2/Phase 3	2012-03-01	This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis .
NCT02050321 ↗	A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma	Terminated	University of Arizona	Phase 2	2013-12-01	We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent.
NCT02113904 ↗	Clinical Trial Using Humira in Netherton Syndrome	Completed	Assistance Publique - Hôpitaux de Paris	Phase 2	2014-01-27	The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment period follow-up of 3 months. Second objectives are To evaluate the safety of Adalimumab in the context of NS To evaluate the improvement of the quality of life at 3 months To evaluate the improvement of pruritus and pain in the patients To study markers of inflammatory and allergy in NS prior and after treatment Benefit of the study An improvement by at least 20% of the cutaneous signs in these patients who suffer from a genetic incurable, chronic, painful and very afflicting disease would be of a great help for these patients. NS is a major source of social exclusion. Risks They are inherent to the risks of biotherapies, especially for an anti-TNF therapy, they comprise a risk of infection. Cutaneous infections occur mainly during infancy, and we have therefore chosen to treat patients over 4 years of age in this study. A close clinical surveillance will be set up (initially every week during the first month of treatment, then every month). This will represents a large number of visits but will provide a high level of security. Benefits/risks ratio In the absence of curative treatment for these patients with a severe genetic skin disease, the benefits/risks ration clearly appears to be in favour of an expected benefit.
NCT03529955 ↗	Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis	Completed	Tulane University	Phase 2	2018-06-12	With limited treatment options available for dermatomyositis, the investigators hypothesize that apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, is a safe and efficacious add-on treatment in patients with refractory cutaneous dermatomyositis. The study will investigate the efficacy, safety and toxicity of apremilast given at 30 mg twice daily to patients with refractory cutaneous dermatomyositis. Clinical response will be assessed at 1 and 3 months. Patients will also be evaluated for durability of their response for up to 6 months. Treatment will be monitored with frequent clinical visits (0, 1, 3 and 6 months) and blood tests (CBC, CMP, creatine kinase, aldolase). Treatment will be discontinued at disease progression or unacceptable adverse events. Disease progression is defined as 4 points increase in the cutaneous dermatomyositis disease area and severity index (CDASI) score, worsening of muscle disease by manual muscle testing (MMT-8) score and 5 points increase in dermatomyositis life quality index (DLQI). 5 mm skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment for gene expression profiling and confirmatory immunohistochemical stains.

Clinical Trial Conditions for SORIATANE

Condition Name

Condition Name for SORIATANE
Intervention	Trials
Malignant Melanoma	1
Netherton Syndrome	1
Psoriasis	1
Chronic Hand Dermatitis	1

Condition MeSH

Condition MeSH for SORIATANE
Intervention	Trials
Psoriasis	1
Dermatomyositis	1
Syndrome	1
Netherton Syndrome	1

Clinical Trial Locations for SORIATANE

Trials by Country

Trials by Country for SORIATANE
Location	Trials
United States	2
Canada	2
France	1

Trials by US State

Trials by US State for SORIATANE
Location	Trials
Louisiana	1
Arizona	1

Clinical Trial Progress for SORIATANE

Clinical Trial Phase

Clinical Trial Phase for SORIATANE
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for SORIATANE
Clinical Trial Phase	Trials
Completed	4
Terminated	1

Clinical Trial Sponsors for SORIATANE

Sponsor Name

Sponsor Name for SORIATANE
Sponsor	Trials
Connetics Corp.	1
University of Medicine and Dentistry of New Jersey	1
Tribute Pharmaceuticals	1

Sponsor Type

Sponsor Type for SORIATANE
Sponsor	Trials
Other	6
Industry	1